Terms: = Gastric cancer AND DDX3X, DDX14, 1654, ENSG00000215301, DBX, DDX3, HLP2 AND Treatment
4 results:
1. Cytosponge-trefoil factor 3 versus usual care to identify Barrett's oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial.
Fitzgerald RC; di Pietro M; O'Donovan M; Maroni R; Muldrew B; Debiram-Beecham I; Gehrung M; Offman J; Tripathi M; Smith SG; Aigret B; Walter FM; Rubin G; ; Sasieni P
Lancet; 2020 Aug; 396(10247):333-344. PubMed ID: 32738955
[TBL] [Abstract] [Full Text] [Related]
2. Influence of sex on chemotherapy efficacy and toxicity in oesophagogastric cancer: A pooled analysis of four randomised trials.
Davidson M; Wagner AD; Kouvelakis K; Nanji H; Starling N; Chau I; Watkins D; Rao S; Peckitt C; Cunningham D
Eur J Cancer; 2019 Nov; 121():40-47. PubMed ID: 31542640
[TBL] [Abstract] [Full Text] [Related]
3. [Value of radical lymph node dissection (compartment I and II) in stomach carcinoma].
Böttcher K; Roder JD; Siewert JR
Zentralbl Chir; 1996; 121(2):131-8. PubMed ID: 8868609
[TBL] [Abstract] [Full Text] [Related]
4. Prognostic relevance of systematic lymph node dissection in gastric carcinoma. German gastric Carcinoma Study Group.
Siewert JR; Böttcher K; Roder JD; Busch R; Hermanek P; Meyer HJ
Br J Surg; 1993 Aug; 80(8):1015-8. PubMed ID: 8402053
[TBL] [Abstract] [Full Text] [Related]
